Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 29.
doi: 10.1002/ana.78024. Online ahead of print.

Co-Opting MBNL-Dependent Alternative Splicing Cassette Exons to Control Gene Therapy in Myotonic Dystrophy

Samuel T Carrell  1   2 , Ellie M Carrell  2 , Ryan Giovenco  2 , Beverly L Davidson  2   3
Affiliations

Co-Opting MBNL-Dependent Alternative Splicing Cassette Exons to Control Gene Therapy in Myotonic Dystrophy

Samuel T Carrell et al. Ann Neurol. .

Abstract

Objective: Myotonic dystrophy type 1 (DM1) is a highly variable, multisystemic genetic disorder caused by a CTG repeat expansion in the 3' untranslated region of DMPK. Toxicity is exerted by repeat-containing DMPK transcripts that sequester muscleblind-like (MBNL) proteins and lead to deleterious yet predictable changes in alternative splicing. To contend with high phenotypic and molecular variability that complicate application of viral-based therapies, we develop and test a DM1-responsive genetic element to control viral-based therapeutic output.

Methods: We used MBNL-dependent cassette exons to generate adeno-associated virus (AAV)-compatible control elements (DMXon). Minigenes were tested in vitro using a Dox-inducible MBNL1 cell model and induced pluripotent stem cell (iPSC)-derived DM1 myotubes and in vivo using DM1 model mice following intramuscular and systemic AAV injection. DMXon splicing, correction of endogenous splicing or skeletal muscle myotonia, and prevention of cardiac toxicity associated with therapeutic MBNL1 overexpression were assessed.

Results: DMXon cassettes respond to MBNL1 dose or expression of CUG repeat RNA. DMXon controlled expression of therapeutic MBNL1 protein can improve skeletal muscle myotonia or prevent cardiac toxicity due to MBNL1 overexpression in mice.

Interpretation: DMXon control elements can increase the therapeutic window of viral-based therapeutics in DM1, and activity is dependent upon delivered cargo and model severity. ANN NEUROL 2025.

PubMed Disclaimer

References

    1. Mendell JR, Al‐Zaidy S, Shell R, et al. Single‐dose gene‐replacement therapy for spinal muscular atrophy. N Engl J Med 2017;377:1713–1722.
    1. Zaidman CM, Proud CM, McDonald CM, et al. Delandistrogene Moxeparvovec gene therapy in ambulatory patients (aged ≥4 to <8 years) with Duchenne muscular dystrophy: 1‐year interim results from study SRP‐9001‐103 (ENDEAVOR). Ann Neurol 2023;94:955–968.
    1. Aimo A, Castiglione V, Rapezzi C, et al. RNA‐targeting and gene editing therapies for transthyretin amyloidosis. Nat Rev Cardiol 2022;19:655–667.
    1. Oskoui M, Caller TA, Parsons JA, et al. Delandistrogene Moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy: evidence in focus: report of the AAN guidelines subcommittee. Neurology 2025;104:e213604.
    1. Tabebordbar M, Lagerborg KA, Stanton A, et al. Directed evolution of a family of AAV capsid variants enabling potent muscle‐directed gene delivery across species. Cell 2021;184:4919–4938.e22.

LinkOut - more resources